Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TREVI THERAPEUTICS, INC.

(TRVI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Trevi Therapeutics, Inc. announced that it has received $3 million in funding from New Enterprise Associates, Inc.

10/18/2021 EST

On October 18, 2021, Trevi Therapeutics, Inc. closed the transaction. The company received funding from 1 investor pursuant to exemption provided under Regulation D.


ę S&P Capital IQ 2021
All news about TREVI THERAPEUTICS, INC.
11/15Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inf..
PR
11/11Needham Adjusts Price Target on Trevi Therapeutics to $8 from $10, Keeps Buy Rating
MT
11/10Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update -..
PU
11/10TREVI THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
11/10Trevi Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/10Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update
PR
11/10Earnings Flash (TRVI) TREVI THERAPEUTICS Reports Q3 Loss $-0.34, vs. Street Est of $-0...
MT
11/09Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference
PR
11/03Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update o..
PR
10/20Trevi Therapeutics, Inc. announced that it has received $11.819892 million in funding
CI
More news
Analyst Recommendations on TREVI THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -34,2 M - -
Net Debt 2021 - - -
P/E ratio 2021 -0,62x
Yield 2021 -
Capitalization 23,1 M 23,1 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 26
Free-Float 78,3%
Chart TREVI THERAPEUTICS, INC.
Duration : Period :
Trevi Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TREVI THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,89 $
Average target price 8,00 $
Spread / Average Target 795%
EPS Revisions
Managers and Directors
Jennifer L. Good President, Chief Executive Officer & Director
Lisa Delfini Chief Financial Officer
David P. Meeker Chairman
Thomas R. Sciascia Chief Medical Officer
Danine Summers Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
TREVI THERAPEUTICS, INC.-62.88%24
GILEAD SCIENCES, INC.19.55%87 368
BIONTECH SE243.27%73 106
REGENERON PHARMACEUTICALS31.46%66 402
WUXI APPTEC CO., LTD.24.26%63 075
VERTEX PHARMACEUTICALS-13.17%52 178